Global Cystatin C Assay Market Size Study & Forecast, by Product (Analyzers, Kits, Reagents), by Method (ELISA, PETIA, PENIA, CLIA, IFA, Others), by Sample Type (Blood, Urine), by Application (Diagnostics, Research), by End-user (Hospitals, Clinical Labor

Global Cystatin C Assay Market Size Study & Forecast, by Product (Analyzers, Kits, Reagents), by Method (ELISA, PETIA, PENIA, CLIA, IFA, Others), by Sample Type (Blood, Urine), by Application (Diagnostics, Research), by End-user (Hospitals, Clinical Laboratories, Pharmaceutical and Biotechnology Companies & CROs & Academic research institutes), and Regional Analysis, 2023-2030

Global Cystatin C Assay Market is valued at approximately USD 350.70 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7.5% during the forecast period 2023-2030. The Cystatin C assay is a diagnostic test that measures the levels of cystatin C in the blood, a protein produced by cells and filtered through the kidneys. Cystatin C is less affected by age and muscle mass compared to conventional kidney function measures. This test is useful for monitoring kidney disorders, determining the glomerular filtration rate, and evaluating renal function. It offers vital information about general renal health and is used by medical practitioners to inform treatment choices and assess the risk of issues connected to the kidneys. The increasing prevalence of kidney diseases, supportive government policies, surge in healthcare expenditure, as well as flourishing growth of the biotechnology and biopharmaceutical industries, are the most prominent factors that are bolstering the market demand across the globe.

Additionally, the growing incidences of chronic kidney diseases are expected to boost the Cystatin C Assay Market. A 2022 report from the Centers for Disease Control and Prevention (CDC) reveals that over 14% of U.S. adults, approximately 37 million individuals, suffer from CKD. Consequently, with the rising prevalence of chronic kidney diseases worldwide, there is an increasing demand for reliable diagnostic solutions to measure cystatin C concentration, thereby propelling market expansion. Also, the growing geriatric population base is further presenting various growth prospects for market expansion as they are more prone to be affected by the CKD and various chronic diseases due to their weak immune system. As per the United Nations, there were 703 million persons aged 65 years or over in the world in 2019. The figure for aged persons is projected to get double and reach 1.5 billion by 2050. Thereby, the demand for cystatin C assays is expected to increase as the growing incidences of chronic kidney diseases, along with the global population age. Moreover, the increasing adoption of point of care testing, as well as the rising focus on the development of condition-specific biomarkers and tests presents various lucrative opportunities over the forecast years. However, the high development costs of cystatin C assays and stringent requirements for approval of cystatin C assay instruments and consumables are hindering market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cystatin C Assay Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the stringent regulatory standards, an increasing trend in healthcare expenditure, the growing prevalence of chronic kidney diseases, the increasing elderly population, and the high presence of manufacturers specializing in cystatin C assays. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The surge in health awareness, escalating healthcare spending, the growth of medical tourism, and the expanding geriatric demographic are significantly propelling the market demand across the region. The rise in the elderly population is associated with a higher incidence of nephros diseases. Consequently, the increase in kidney diseases leading to the expansion of this demographic is directly stimulating the demand for cystatin C assay products. This, in turn, is fostering growing research and development activities and strategic initiatives by key industry players.

Major market players included in this report are:
Abbott (US)
Roche Diagnostics Limited (Switzerland)
Siemens Healthineers AG (Germany)
Thermo Fisher Scientific Inc. (US)
Randox Laboratories Ltd. (UK)
DiaSys Diagnostic Systems GmbH (Germany)
Bio-Techne (US)
Gentian Diagnostics ASA (Norway)
Getein Biotech, Inc. (China)
Agilent Technologies, Inc. (US)

Recent Developments in the Market:
 In March 2021, Roche completed the acquisition of GenMark Diagnostics, purchasing each share for USD 24.05 and achieving a total transaction value of USD 1.8 billion. This strategic move significantly bolstered Roche's Diagnostics portfolio.
 In March 2022, Gentian- a leading participant in the cystatin C test industry announced that TüV SÜD has validated their GCAL and Cystatin C assays for IVDR (In-Vitro Diagnostic Regulation). The assays meet the regulatory requirements outlined by IVDR, as indicated by this certification. This strategic introduction aimed to increase income and broaden its services.

Global Cystatin C Assay Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Method, Sample Type, Application, End-user, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Analyzers
Kits
Reagents

By Method:
Enzyme-Linked Immunosorbent Assay (ELISA)
Particle-Enhanced Turbidimetric Immunoassay (PETIA)
Particle-enhanced Nephelometric Immunoassay (PENIA)
Chemiluminescent immunoassay (CLIA)
Immunofluorescence assay (IFA)
Others

By Sample Type:
Blood
Urine

By Application:
Diagnostics
Research

By End-user:
Hospitals
Clinical Laboratories
Pharmaceutical and Biotechnology Companies & CROs & Academic research institutes

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.